GreenLight Biosciences Holdings
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRNA research report →
Range $4 – $18
Price Chart
About the company
GreenLight Biosciences Holdings is a biotechnology firm focused on developing and commercializing ribonucleic acid (RNA) solutions. Its innovative products serve both the human health and agricultural industries. The company's human health portfolio includes mRNA vaccines and various therapeutic treatments, while its agricultural offerings feature RNA-based innovations designed to protect honeybees and defend crops.
- CEO
- Andrey Juan Zarur
- IPO
- 2022
- Employees
- 280
- HQ
- Medford, MA, US
Get TickerSpark's AI analysis on GRNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.43M
- P/E
- -0.24
- PEG
- 0.00
- P/S
- 7.12
- P/B
- 0.82
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -2567.65%
- Net Margin
- -2616.78%
- ROE
- -1847.24%
- ROIC
- -126.46%
Latest fiscal year · YoY change
- Revenue
- $6.38M+0.0%
- Gross Profit
- $6.38M+0.0%
- Op Income
- $-163,919,000
- Net Income
- $-167,055,000-45.6%
- EPS
- $-1.27-36.6%
- OCF Growth
- -48.9%
- FCF Growth
- -52.6%
- 52W High
- $5.90
- 52W Low
- $0.18
- 50D MA
- $0.27
- 200D MA
- $0.85
- Beta
- 1.44
- RSI (14)
- 59
- Avg Volume
- 684.80K
No earnings-call transcripts are available for GRNA yet.
- Free Float
- 0.0%
- Shares Outstanding
- 151.68M
- Float Shares
- 0
of shares held by institutions
60 13F filers
Buy/sell ratio 0.02. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Etf Managers Group, LLC | 51.55K | ▲ 13.76K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 24, 23 | KODIAK VENTURE PARTNERS III LP | other | 9,809,895 |
| May 29, 23 | KODIAK VENTURE PARTNERS III LP | other | 0 |
| Jul 24, 23 | Clarke Dennis A. | other | 25,510.204 |
| Jul 24, 23 | Anderson Eric Senior | other | 25,510.204 |
| Jul 24, 23 | Cummings Foundation, Inc. | other | 1,275,510.204 |
| Jul 24, 23 | COONEY CHARLES L | other | 305,314 |
| Jul 24, 23 | Insud Pharma S.L. | other | 2,551,020 |
| May 29, 23 | MLS Capital Fund II LP | other | 0 |
| Jul 24, 23 | MLS Capital Fund II LP | other | 5,818,575 |
| Jul 24, 23 | PATRICK DEVAL L | other | 172,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GRNA coverage
Recent articles, reports, and earnings notes.
No research on GRNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRNA report →GreenLight Announces Completion of Merger with Fall Line Endurance Fund
globenewswire.com · Jul 24
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
globenewswire.com · Jul 20
Why Greenlight Biosciences Stock Was in the Red Today
fool.com · Dec 8
GreenLight Biosciences to cut 25% of its workforce as part of ‘realignment' to extend cash runway
marketwatch.com · Oct 12
Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More
benzinga.com · Aug 16
Why GreenLight Biosciences Stock Is Crushing It Today
fool.com · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.